The short version of RP-HPLC fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-06-01. Anything still debated is marked as such rather than presented as settled.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
Most of the rest of the world excluded prisoners as potential research subjects following formulation of the Nuremberg Code, based on its assertion that acceptable experimental subjects must be "so situated as to be able to exercise free power of choice". Despite regulations that limit circumstances where inclusion of vulnerable populations in clinical trials is permitted, such groups, such the economically disadvantaged, continue to be made part of research through coercive means as recently as 2015. International clinical trials day is celebrated on 20 May. The acronyms used in the titling of clinical trials are often contrived, and have been the subject of derision.
=== Sunlight === There is evidence that β-endorphin is released in response to ultraviolet radiation, either through sun exposure or artificial tanning. This is thought to contribute to addiction behavior among excessive sunbathers and users of artificial tanning despite health risks.
== History == Vaccine storage was first developed in the early 1960s, when the infectious smallpox disease outbreaks. During this time, vaccine technology was available and offered for protection. Since smallpox has been one of the deadliest diseases known, the World Health Organization (WHO) prepared to launch a campaign to spread the vaccines and end smallpox in 1966. It was not until 1974 where WHO first introduced the Expanded Programme on Immunization (EPI). The main goal was to make immunization available to every child worldwide by 1990. Immunization of six illnesses was being transported, including tuberculosis, diphtheria, pertussis, tetanus, measles, and polio. Dr. Rafe Henderson, the first director of EPI, designed a plan to deliver temperature-sensitive vaccines across dozens of countries safely. It was an important step to ensure that the vaccines were maintained in their determined conditions and guides towards the development of the cold chain. The WHO supported countries worldwide to ensure the vaccine cold chain is maintained. The cold chain has been implemented for years. After EPI was initiated, over 700,000 measles deaths were prevented, and millions of the target diseases have been prevented. There has been a huge milestone in the vaccine industry as scientists create more vaccines for new types of diseases. Therefore, it has a direct impact on the cost of transportation and different kinds of refrigerator storage either at +2° to +8 °C or +20° to +25 °C.
Media related to Taxidermy at Wikimedia Commons Taxidermy.blog Archived 2021-06-24 at the Wayback Machine Taxidermy.Net Methods in the Art of Taxidermy Archived 2010-10-31 at the Wayback Machine by Oliver Davie Free Taxidermy School.Com
On 22 December 1988, the Brazzaville Protocol was enshrined in the Tripartite Accord, which required the SADF to withdraw from Angola and reduce its troop levels in South West Africa to a token force of 1,500 within twelve weeks. Simultaneously, all Cuban brigades would be withdrawn from the border to an area north of the 15th parallel. At least 3,000 Cuban military personnel would depart Angola by April 1989, with another 25,000 leaving within the next six months. The remaining troops would depart at a date not later than 1 July 1991. An additional condition was that South Africa would cease all support for UNITA, and Angola likewise for PLAN and MK. On 20 December 1988, United Nations Security Council Resolution 626 was passed, creating the United Nations Angola Verification Mission (UNAVEM) to verify the redeployment northwards and subsequent withdrawal of the Cuban forces from Angola. UNAVEM included observers from Western as well as non-aligned and communist nations. In February 1989 the United Nations Transition Assistance Group (UNTAG) was formed to monitor the South West African peace process.
Sources: en.wikipedia.org
nickase Another name for a nicking enzyme, especially one that has been artificially engineered to create single-stranded breaks (i.e. nicks) by altering the cleavage activity of an endonuclease that normally creates double-stranded breaks, e.g. Cas9 nickase (nCas9).
According to the 2021 Romanian census, Romania's population was 19,053,815. Like other countries in the region, its population is expected to decline gradually as a result of sub-replacement fertility rates and negative net migration rate. According to the 2021 Romanian census, Romanians made up 89.33% of the population, Hungarians 6.05% and the Roma 3.44% of the population, but many ethnicities are not recorded, as they do not have ID cards. International sources give higher figures for Roma than the official census. According to the Council of Europe, the Roma make up 8.32% of the population; this figure is difficult to verify due to the mobility of Roma and the reluctance of some of them to disclose their ethnicity. Hungarians constitute a majority in the counties of Harghita and Covasna. Other minorities include Ukrainians, Germans, Turks, Lipovans, Aromanians, Tatars, and Serbs. In 1930, there were 745,421 Germans living in Romania, but only about 36,000 remained in the country to this day. As of 2009, there were also approximately 133,000 immigrants living in Romania, primarily from Moldova and China. The total fertility rate (TFR) in 2018 was estimated at 1.36 children born per woman, which is below the replacement rate of 2.1, and one of the lowest in the world; it remains considerably below the high of 5.82 children born per woman in 1912. In 2014, 31.2% of births were to unmarried women.
Tetrabenazine was approved in 2000 for treatment of chorea in Huntington's disease in the EU, and in 2008 in the US. Although other drugs had been used "off label", tetrabenazine was the first approved treatment for Huntington's disease in the US. The compound has been known since the 1950s. In 2017, deutetrabenazine, a heavier form of tetrabenazine medication for the treatment of chorea in HD, was approved by the FDA. This is marketed as Austedo. Valbenazine (Ingrezza) was also approved by the FDA for the treatment of Huntington's disease chorea in 2023. Tetrabenazine, deutetrabenazine, and valbenazine are all vesicular monoamine transporter 2 (VMAT2) inhibitors, which work by depleting dopamine in the brain, lessening involuntary movements. These are the only drugs that have been approved specifically for Huntington's disease (namely the chorea associated with it). Other drugs that help to reduce chorea include antipsychotics and benzodiazepines. Hypokinesia and rigidity, especially in juvenile cases, can be treated with antiparkinsonian drugs, and myoclonic hyperkinesia can be treated with valproic acid. Tentative evidence has found ethyl eicosapentaenoic acid to improve motor symptoms at one year. Amantadine has also been used to treat chorea, but there is limited evidence for its safety and efficacy. Psychiatric symptoms can be treated with medications similar to those used in the general population.
== Clinical significance == There are two congenital disorders of the long bones. In a disorder known as rachitis fetalis anularis the ends of the long bones (epiphyses) are enlarged. Another disorder, rachitis fetalis micromelica, is a deficiency in the growth (as a shortness) of the bones. There is a surgical procedure called distraction osteogenesis which is used to lengthen long bones.
== Analytical method == Protein deamidation has been commonly analyzed by reverse-phase liquid chromatography (RPLC) through peptide mapping. Recently reported novel ERLIC-MS/MS method would enhance the separation of deamidated and non-deamidated peptides with increased identification and quantitation quantification. Mass spectrometry is commonly used to characterize deamidation states of proteins, including therapeutic monoclonal antibodies. The technique is especially useful for deamidation analysis due to its high sensitivity, speed, and specificity. This allows site-specific deamidation analysis. A major challenge of using mass spectrometry is the formation of deamidation artifacts during sample preparation. These artifacts significantly skew results because they suggest greater rates of spontaneous deamidation than what is truly observed. This can prove problematic in the case of therapeutic proteins which can be mischaracterized in QC protocols if a large percentage of detected deamidation is due to artifacts. Recent studies indicate that lower pH can reduce the rate of deamidation artifacts.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.